Related Experiment Video

Updated: Apr 20, 2026

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

11.9K

CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer

Edmond Chipumuro1, Eugenio Marco2, Camilla L Christensen3

  • 1Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

Cell
|November 24, 2014
PubMed

Insights

Targeting cyclin-dependent kinase 7 (CDK7) inhibits MYCN-driven gene amplification in neuroblastoma. This approach suppressed tumor growth in mice, offering a potential new cancer therapy without systemic toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • MYC oncoproteins drive tumor growth via gene transcription amplification.
  • Inhibiting MYC function has been challenging for cancer therapy.
  • Neuroblastoma often involves MYCN amplification, leading to aggressive disease.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting cyclin-dependent kinase 7 (CDK7) in MYCN-amplified neuroblastoma.
  • To assess the impact of CDK7 inhibition on MYCN-driven transcription and tumor growth.

Main Methods:

  • Utilized a covalent inhibitor targeting CDK7 in neuroblastoma cells.
  • Analyzed the downregulation of MYCN oncoprotein and global transcriptional amplification.
  • Evaluated tumor regression and systemic toxicity in a mouse model of high-risk neuroblastoma.

Main Results:

  • CDK7 inhibition led to MYCN downregulation and suppressed MYCN-driven transcriptional amplification.
  • Significant tumor regression was observed in a mouse model without systemic toxicity.
  • Treatment selectively targeted MYCN-overexpressing cells by downregulating super-enhancer-associated genes.

Conclusions:

  • CDK7 inhibition selectively targets MYCN-driven global transcriptional amplification.
  • This approach shows promise as a novel therapeutic strategy for MYC-driven cancers, including neuroblastoma.
  • Selective targeting of transcriptional mechanisms offers a new avenue for cancer treatment.

More Related Videos

Genome-wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN11:42

Genome-wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN

Published on: April 3, 2026

70
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K